Literature DB >> 18283144

Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators.

Michael A Zimmerman1, R Mark Ghobrial, Myron J Tong, Jonathan R Hiatt, Andrew M Cameron, Johnny Hong, Ronald W Busuttil.   

Abstract

OBJECTIVE: To review the preoperative and postoperative variables that predict hepatocellular carcinoma (HCC) recurrence following orthotopic liver transplantation (OLT). DATA SOURCES: A collective review of the literature was conducted by searching the MEDLINE database using several key words: hepatocellular carcinoma, recurrence, liver transplantation, and salvage transplantation. STUDY SELECTION: Reviews and original articles containing basic scientific observations and long-term clinical outcomes were included. DATA EXTRACTION: Critical observations from peer-reviewed sources were incorporated in this review. DATA SYNTHESIS: Overall, 11 studies were reviewed to determine the incidence of HCC recurrence following OLT and to identify prognostic variables of recurrence. Four studies were evaluated to determine the efficacy of salvage transplantation following liver resection.
CONCLUSIONS: Liver transplantation is a viable treatment option for select patients with HCC and end-stage liver disease. However, in approximately 20% of patients, recurrent HCC is the rate-limiting factor for long-term survival. Despite identification of clinical parameters that may stratify patients at high risk and exhaustive preoperative staging, cancer recurrence is likely the result of microscopic extrahepatic disease. With a desperate donor organ shortage, locoregional ablation techniques and resection are being employed in patients on the waiting list to serve as a bridge to OLT. Furthermore, some have advocated aggressive surgical resection of isolated metastasis in both the liver and extrahepatic viscera. Whether these creative strategies confer a survival advantage is unknown; it will require long-term follow-up to determine their efficacy.

Entities:  

Mesh:

Year:  2008        PMID: 18283144     DOI: 10.1001/archsurg.2007.39

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  99 in total

1.  Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Neil Mehta; Francis Y Yao; John P Roberts
Journal:  Clin Transplant       Date:  2014-12-01       Impact factor: 2.863

2.  Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Hong-Yuan Chen; Jun-Wei Fan; Jun-Yi Wu; Hua-Mei Tang; Zhi-Hai Peng
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-10       Impact factor: 4.553

Review 3.  Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.

Authors:  J U Marquardt; V M Factor; S S Thorgeirsson
Journal:  J Hepatol       Date:  2010-05-31       Impact factor: 25.083

Review 4.  Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.

Authors:  Nicola de'Angelis; Filippo Landi; Maria Clotilde Carra; Daniel Azoulay
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

5.  Can we direct organ allocation based on predicted outcome? Hepatocellular carcinoma outside of UCSF criteria or retransplant?

Authors:  Caroline Rochon; Patricia Sheiner; Basant Mahadevappa; Ganesh Gunasekaran; Joyti Sharma; David C Wolf; Marcelo Facciuto
Journal:  Langenbecks Arch Surg       Date:  2012-01-28       Impact factor: 3.445

Review 6.  Management of hepatocellular carcinoma.

Authors:  P Fitzmorris; M Shoreibah; B S Anand; A K Singal
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-27       Impact factor: 4.553

7.  The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma.

Authors:  Gaya Spolverato; Alessandro Vitale; Aslam Ejaz; Yuhree Kim; Shishir K Maithel; David P Cosgrove; Timothy M Pawlik
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

8.  Plasminogen fragment K1-3 inhibits expression of adhesion molecules and experimental HCC recurrence in the liver.

Authors:  Esther Raskopf; Sevil Gerceker; Annabelle Vogt; Jens Standop; Tilman Sauerbruch; Volker Schmitz
Journal:  Int J Colorectal Dis       Date:  2009-01-27       Impact factor: 2.571

9.  Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Lin Zhong; Mu-Jian Teng; Jun-Wei Fan; Hua-Mei Tang; Jun-Yi Wu; Hong-Yuan Chen; Zhao-Wen Wang; Guo-Qiang Qiu; Zhi-Hai Peng
Journal:  Mol Oncol       Date:  2012-04-17       Impact factor: 6.603

10.  The role of liver transplantation or resection for patients with early hepatocellular carcinoma.

Authors:  Kuan-Chun Hsueh; Ting-Ying Lee; Chew-Teng Kor; Tsung-Ming Chen; Tzu-Ming Chang; Shun-Fa Yang; Chung-Bao Hsieh
Journal:  Tumour Biol       Date:  2015-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.